Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
FDA Approves argenx's VYVGART Hytrulo: Subcutaneous Treatment for Generalized Myasthenia Gravis
argenx SE, a global immunology company focused on improving the lives of individuals with severe autoimmune diseases, has announced the approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) by the U.S. Food and Drug Administration (FDA)....
Innovent and IASO Bio Gain NMPA Approval for FUCASO®, a Breakthrough BCMA CAR-T Therapy for Multiple Myeloma
Innovent Biologics, Inc. (HKEX: 01801) and IASO Biotechnology have jointly announced the approval of FUCASO® by the National Medical Products Administration (NMPA) in China....
Amicus Therapeutics Secures Approval and Launches New Therapy for Pompe Disease in the European Union
Amicus Therapeutics, a global biotechnology company focused on rare diseases, has announced the approval of Opfolda® (miglustat) 65mg capsules by the European Commission (EC). Opfolda is an enzyme stabilizer used in combination with Pombiliti® (cipaglucosidase alfa), an enzyme replacement therapy for adults with late-onset Pompe disease....
FDA Grants 505(b) (2) NDA Approval to Amneal for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has announced the approval of PEMRYDI RTU® under a 505(b)(2) New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA). This innovative product is the first of its kind as a ready-to-use presentation of pemetrexed for injection, eliminating the need for reconstitution, dilution, or refrigeration....
FDA Grants Approval to Sarepta Therapeutics' ELEVIDYS, a Breakthrough Gene Therapy for Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ELEVIDYS (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene....
Novel Breakthrough: Activating G-Protein Coupled Receptors from Within Cells Paves the Way for Side Effect-Free Drug Development
Researchers have recently made a remarkable discovery related to the activation of a G-protein coupled receptor (GPCR) known as the human parathyroid hormone type 1 receptor (PTH1R). This discovery pertains to a new mode of receptor activation that occurs within cells, without the involvement of signal transduction from the extracellular side....
Major Advancement: Successful Direct Sequencing of Functional Antibody Proteins from Human Blood
Rapid Novor Inc., a prominent leader in mass spectrometry (MS)-based antibody protein sequencing, has achieved a significant breakthrough. The company's REpAb® antibody discovery platform has successfully sequenced a complex mixture of functional antibodies directly from the serum of a human patient who received a COVID-19 vaccine. This accomplishment represents a remarkable advancement in antibody discovery technology, eliminating the reliance on animal models, DNA, and cells. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor, highlights the potential of sequencing...
BeaMed Technologies Achieves Breakthrough in Fiber Optic Probe Development for StingRay Laser System, Paving the Way for Revolutionary Integration Testing
Innovation Pharmaceuticals (OTCQB:IPIX), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (BeaMed), has announced significant progress in the development of BeaMed's StingRay Laser system. BeaMed reported a major technical milestone with the completion of its first-ever MRI compatible fiber optic probes, a crucial step in advancing its laser technology for personalized epilepsy and cancer surgery. Integration tests, involving the unique MRI compatible fiber optics, an MRI interface software suite, damage estimation algorithms, and custom insertion tools, are planned to begin in late June 2023....
Revolutionary AI-Based Estimator Transforms Medicine Manufacturing
A collaborative research team consisting of scientists from the MIT-Takeda Program has developed an innovative method that combines physics and machine learning to analyze the rough surfaces of particles in pharmaceutical pills and powders. The goal of this research is to improve the manufacturing process of pharmaceutical products by reducing subjectivity and enhancing efficiency....
UCI Researchers Develop Highly Targeted DNA Enzyme for Gene Silencing at the Single-Molecule Level
Researchers at the University of California, Irvine (UCI) have made a significant breakthrough by developing a DNA enzyme, or DNAzyme, that can differentiate between two RNA strands within a cell. This groundbreaking technology enables the DNAzyme to selectively target and cut disease-associated RNA strands while leaving healthy strands intact. The potential applications of this "gene silencing" technology are vast, with implications for treating cancer, infectious diseases, and neurological disorders....
